Huons BioPharma announced on Monday that it has inked a deal with the wholly-owned distribution subsidiary of its Chinese partner, iMaker Technology, for the supply of botulinum toxin. The company has already shipped its initial batch.
HUTOX, a cosmetic and therapeutic drug, primarily contains botulinum toxin type A (Clostridium botulinum toxin). It’s widely used for reducing the appearance of frown lines and crow’s feet.
In 2022, iMaker secured exclusive import and distribution rights for botulinum toxin products in China from Huons BioPharma.
After extensive development efforts in China, iMaker received approval from the National Medical Products Administration (NMPA) of China for HuTox at 100 units in January.
The shipped HuTox is slated for quality inspections by Chinese health authorities and is expected to hit the market in the latter half of this year. This milestone makes HuTox the seventh botulinum toxin product to be commercialized in China, and the second from a South Korean company.
A spokesperson for Huons BioPharma stated that this initial shipment marks the beginning of the close collaboration with iMaker to ensure smooth distribution and effective marketing in China. They’re optimistic that HUTOX will generate substantial global revenue starting this year.
